HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances IND-Enabling Studies
Dual-target fusion protein extends HanchorBio’s FBDB™ beyond oncology into high-need immune-mediated diseases
[Taipei, Shanghai, San Francisco | May 11, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced HCB206, the company’s internally developed dual-target fusion protein candidate, is advancing toward IND-enabling studies following preclinical data supporting its potential application across oncology and autoimmune diseases.
HCB206 is built on HanchorBio’s proprietary FBDB™ platform and is designed to combine targeted cell binding and Fc-mediated immune effector functions, including antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. By engaging immune clearance mechanisms against pathogenic or abnormal cells, HCB206 is being evaluated as a potential therapeutic candidate in both malignant B-cell diseases and autoimmune diseases characterized by pathogenic B-cell activity.
In preclinical studies, HCB206 demonstrated tumor growth inhibition across multiple animal tumor models and showed therapeutic potential in immune disease models. HanchorBio has also generated pharmacology data supporting HCB206’s ability to modulate immune cell activity and improve immune microenvironment responses, providing a rationale further IND-enabling development.
“HCB206 is being developed to evaluate whether a dual-target fusion protein approach can extend oncology into autoimmune diseases where pathogenic immune cells contribute to disease activity and relapse,” said Wen-Wu Zhai, Ph.D., Chief Research and Development Officer of HanchorBio. “Based on the preclinical data generated to date, we are advancing formal toxicology studies and other IND-enabling activities while assessing the clinical development pathways in selected autoimmune disease indications.”
“HCB206 represents an important step in HanchorBio’s broader platform strategy,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “Our goal is to build a differentiated pipeline of next-generation fusion protein therapeutics that can address complex immune biology across both oncology and immune-mediated diseases. The expansion of HCB206 into autoimmune disease reflects the versatility of our FBDB™ platform and our commitment to developing biologics with global clinical and partnering potential.”
Autoimmune diseases affect a substantial portion of the global population, and many patients require chronic treatment with therapies that may be limited by incomplete response, relapse, infection risk, or long-term immunosuppression. HanchorBio is pursuing a dual-track autoimmune research strategy that includes targeted depletion of pathogenic B-cells as well as multifunctional immune-modulating biologics designed to address T-cell regulation and cytokine-driven inflammation.
HanchorBio currently has two FBDB™-derived drug candidates in clinical development and continues to leverage its platform capabilities to expand its oncology and autoimmune disease pipeline. The company plans to advance HCB206 through IND-enabling studies while exploring and partnering opportunities for next-generation immunotherapies.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.